Toxicity rates high after cetuximab therapy for anal carcinoma

The addition of cetuximab to chemoradiotherapy was associated with a lower incidence of locoregional failure in patients with squamous cell carcinoma of the anal canal, according to results from the phase 2 Eastern Cooperative Oncology Group—American College of Radiology Imaging Network Cancer Research Group Trial.